The Rs 570.00 crore Innova Captab IPO was a book-built offering. The offering for sale of 0.56 crore shares and a new issue of Rs 320.00 crore comprised this issue.
The subscription period for the Innova Captab IPO began on December 21, 2023, and ended on December 26, 2023. On Wednesday, December 27, 2023, the allotment for the Innova Captab IPO was anticipated to be completed. The BSE and NSE offered the Innova Captab IPO, with a provisional listing date of Friday, December 29, 2023.
The pricing range for the Innova Captab IPO was ₹426 to ₹448 per share. 33 Shares were the minimum lot size required for an application. Retail investors were required to invest a minimum of ₹14,784 to qualify. For both sNII and bNII, the minimum lot size investment was ₹206,976 for 14 lots (462 shares) and ₹1,005,312 for 68 lots (2,244 shares).
Here’s how you can check the Innova Captab IPO allotment status of Innova Captab Limited IPO:
Step 1: Go to the BSE website.
Step 2: Choose ‘Equity’ and then the issue name from the selection menu.
Step 3: Enter your application number as well as your PAN card number and press ‘Search’.
You can also follow a similar procedure to check the Innova Captab IPO allotment status on the Registrar’s website:
Step 1: Go to the Kfin Technologies website.
Step 2: Select the IPO name by searching for the company.
Step 3: Input your PAN, application number, DP/Client ID, or account number/IFSC number and click on ‘Search’.
If the details are input correctly, the status will appear only after allotment. The equity shares are expected to be credited to successful investors’ demat accounts on December 28, 2023.
India’s leading pharmaceutical company, Innova Captab Limited, integrates manufacturing, research, and market penetration both domestically and globally. With their three main strengths—a premier CDMO service for Indian pharmaceutical businesses, a developing portfolio of branded generics sold in India, and an increasing global footprint with exports to 20 countries—they serve a variety of demands. With cutting-edge facilities and a robust R&D engine, Innova Captab is well-positioned to thrive and pave the way for a healthier future for patients everywhere.
Over 600 distinct types of generics were produced and sold by the company in the fiscal year 2023 and the three months that concluded on June 30, 2023. In the Indian market, these goods were supplied under the company’s own trademarks via more than 150,000 retail pharmacies, 5,000 distributors, and stockists.
Furthermore, during FY2023 and the three months that concluded on June 30, 2023, Innova Capitab exported its branded generic products to 20 and 16 countries, respectively.
